EMFLAZA is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Ptc Therapeutics, Inc.. The primary component is Deflazacort.
| Product ID | 52856-503_093eae66-8239-47c7-8cc7-9b4be164fb70 |
| NDC | 52856-503 |
| Product Type | Human Prescription Drug |
| Proprietary Name | EMFLAZA |
| Generic Name | Deflazacort |
| Dosage Form | Tablet |
| Route of Administration | ORAL |
| Marketing Start Date | 2018-09-10 |
| Marketing Category | NDA / NDA |
| Application Number | NDA208684 |
| Labeler Name | PTC Therapeutics, Inc. |
| Substance Name | DEFLAZACORT |
| Active Ingredient Strength | 30 mg/1 |
| Pharm Classes | Corticosteroid [EPC],Corticosteroid Hormone Receptor Agonists [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2022-12-31 |
| Marketing Start Date | 2018-09-10 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA208684 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2018-09-10 |
| Ingredient | Strength |
|---|---|
| DEFLAZACORT | 30 mg/1 |
| SPL SET ID: | 31b347d2-f156-4055-9d8f-7cf0df420296 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 42998-501 | EMFLAZA | deflazacort |
| 42998-502 | EMFLAZA | deflazacort |
| 42998-503 | EMFLAZA | deflazacort |
| 42998-504 | EMFLAZA | deflazacort |
| 42998-505 | EMFLAZA | deflazacort |
| 52856-501 | EMFLAZA | deflazacort |
| 52856-502 | EMFLAZA | deflazacort |
| 52856-503 | EMFLAZA | deflazacort |
| 52856-504 | EMFLAZA | deflazacort |
| 52856-505 | EMFLAZA | deflazacort |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() EMFLAZA 86639624 5261599 Live/Registered |
PTC THERAPEUTICS, INC. 2015-05-22 |